Abstract
“Therapeutic validation” is a utilitarian classification of the application of the basic science base of the macrophage. Reduction to therapeutic practice represents the cutting edge of therapy, but rests upon a decades-old basic science foundation. Macrophage-targeted therapeutics have now added significant value to the lives and quality of life of patients, without undue adverse effects in multiple disease settings. These are exemplified by the impact of macrophage enzyme replacement for a lysosomal storage disease (Gaucher’s), the modulation of osteoclast-dependent bone destruction by bisphosphonates, and revolutionary impact of TNF sequestrants on both rheumatoid arthritis, as well as the delineation of new mechanisms in the understanding of Crohn’s diseases. The macrophage, as a cell, is now beginning to reach a full measure of therapeutic maturity in the application of the understanding of the particular rate-limiting roles that it plays in the maintenance of health or the induction of diseases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Balicki D, Beutler E (2002) Gene therapy of human disease. Medicine 81:69
Bembi B, Ciana G, Mengel E, Terk M, Martini C, Wenstrup R (2002) Bone complications in children with Gaucher disease. Br J Radiol 75:A37
Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ (1999) Farnesol and Geranylgeraniol Prevent Activation of Caspases by Aminobisphosphonates: Biochemical Evidence for Two Distinct Pharmicological Classes of Bisphosphonate Drugs. Molecular Pharmacology 56:131
Berger J, Moller DE (2002) The Mechanisms of Action of PPARS. Annu Rev Medicine 53, no. 1:409
Bresnihan B (2002) Preventing joint damage as the best measure of biologic drug therapy. J Rheumatol 65, no. 29 Sept. Suppl.:39
Coxon FP, Helfrich MH, Van’T Hof R, Sebti S, Ralston HSH A, Rogers MA (2000) Protein Geranylgeranylation is Required for Osteoclast Formation, Function, and Survival: Inhibition by Bisphosphonates and GGTI-298. Journal of Bone and Mineral Research 15, no. 8:1467
Dwek R, Butters T, Platt F, Zitzmann N (2002) Targeting glycosylation as a therapeutic approach. Nature Reviews Drug Discovery 1:65
Ettinger R, Daniel N (2000) TNF-deficient mice develop anti-nuclear autoantiboies. Scand JImmunol 51:S88
Feldmann M, Maini RN (2001) anti-TNF-a therapy of RHEUMATOID arthritis: what have we learned? Annu Rev Immunol 19, no. 1:163
Fisher JE, Rodan GA, Reszka AA (2000) In vivo Effects of Bisphosphonates on the Osteoclast Mevalonate Pathway. Endocrinology 141, no. 12:4793
Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RGG, Rodan GA, Reszka AA (1999) Alendronate mechanism of action: geranylgerniol, and intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96:133
Havell E (1989) Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol 143:2894
Inoue K, Lupski JR (2002) Molecular mechanisms for genomic disorders. Annu Rev Genom Hum Genet 3, no. 1:199
Jenkins JK, Hardy KJ (2002) Biological modifier therapy for the treatment of rheumatoid arthritis. Am J Med Sci 323, no. 4:197
Kalden JR (2002) Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases. Arthritis Res 2, no. 4 Suppl:S34
Karpf D, Shapiro D, Seeman E, Ernsrud K, Johnston CAS, Harris S, Santora A, Hirsch L, Oppenheimer L, Thompson D (1997) Prevention of nonvertebral fractures by alen-dronate: a meta-analysis. J Am Med Assoc 277:1159
Keane J, Gershon S, Wise R, Mirabilie-Levens E, Kasnica J, Schwieterman W, Siegel J, Braun M (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing ag4ent. N Engl J Med 345:1098
Kindler V, Sappino A, Grau G, Piguet P, Vassalli P (1989) The Inducing Role of Tumor Necrosis Factor In the Development of Bactericidal Granulomas during BCG Infection. Cell 56:731
Lenercept Msg (1999) TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study. Neurology 53, no. 3:457
Mayordomo L, Marenco J, Gomez-Mateos J, Rejon E (2002) Pulmonary miliary tuberculosis in a pateint with anti-TNF-alpha treatment. Scand J Rheumatol 31:44
Podolsky D (2002) Inflammatory bowel disease. N Engl J Med 347:417
Poll L, Maas M, Terk M, Roca-Espiau M, Bembi B, Ciana G, Weinreb R (2002) Response of Gaucher bone disease to enzyne replacent therapy. Br J Radiol 75:A25
Reszka AA, Halasy-Nagy J, Masarachia PJ, Rodan GA (1999) Bisphosphonates Act Directly on the Osteoclast to Induce Caspase Cleavage of Mstl Kinase Apoptosis. The Journal of Biological Chemistry 274, no. 49:34967
Sandborn WJ, Targan SR (2002) Biologic therapy of inflammatory bowel disease. Gastroenerology 122, no. 6:1592
Scott DL (2002) Advances in the medical management of rheumatoid arthritis. Hosp Medicine 63, no. 5:1227
Sicotte NL, Voskuhl RR (2001) Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 57, no. 10:1885
Tracey KJ, Cerami A (1994) Tumor necrosis factor: a pleiotropic cytokine and therapuetic target. Annu Rev Medicine 45, no. 1:491
Weinreb N, Charrow J, Andersson H, Kaplan P, Kolodny E, Mistry P, Pastores G, Rosen-bloom B, Scott C, Wappner R, Zimran A. (2002) Effectiveness of enzyme replacement therapy in 1028 pateinest with type I Gaucher disease after 2 to 5 years of treatment. Am J Med 113:112
Weisman MH (2002) What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J Rheumatol 65, no. 29 Sept. Suppl:33
Wright S, Silverstein S (1984) Phagocytosing macrophages exclude proteins from the zones of contact with opsonized targets. Nature 309:359
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Rosen, H. (2003). The Macrophage as a Validated Pharmaceutical Target. In: Gordon, S. (eds) The Macrophage as Therapeutic Target. Handbook of Experimental Pharmacology, vol 158. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-55742-2_1
Download citation
DOI: https://doi.org/10.1007/978-3-642-55742-2_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62919-8
Online ISBN: 978-3-642-55742-2
eBook Packages: Springer Book Archive